sulindac

Summary

Summary: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.

Top Publications

  1. pmc NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling
    Hu Zhou
    Institute for Biomedical Research, Xiamen University, Xiamen, Fujian 361005, China
    Cancer Cell 17:560-73. 2010
  2. pmc Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial
    Frank L Meyskens
    Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, California, USA
    Cancer Prev Res (Phila) 1:32-8. 2008
  3. ncbi The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15
    Jong Sik Kim
    Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, NIH, MD E4 09, P O Box 12233, 111 TW Alexander Drive, Research Triangle Park, NC 27709, USA
    Mol Cancer Ther 4:487-93. 2005
  4. pmc Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds
    Liqun Huang
    Department of Medicine, Division of Cancer Prevention, Stony Brook University, Stony Brook, New York 11794, USA
    Cancer Res 71:7617-27. 2011
  5. pmc The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats
    L Huang
    Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, NY, USA
    Br J Pharmacol 162:1521-33. 2011
  6. pmc Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice
    Gerardo G MacKenzie
    Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA
    Cancer Prev Res (Phila) 4:1052-60. 2011
  7. pmc Intervening in β-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis
    Ulrike Stein
    Experimental and Clinical Research Center, Charite University Medicine, at the Max Delbrück Center for Molecular Medicine, Berlin, Germany
    Neoplasia 13:131-44. 2011
  8. pmc Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits
    H M Verheul
    Department of Surgery, Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Br J Cancer 79:114-8. 1999
  9. pmc Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect
    Liqun Huang
    Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA
    Carcinogenesis 31:1982-90. 2010
  10. pmc Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice
    Gerardo G MacKenzie
    Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, New York 11794 8173, USA
    Gastroenterology 139:1320-32. 2010

Detail Information

Publications237 found, 100 shown here

  1. pmc NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling
    Hu Zhou
    Institute for Biomedical Research, Xiamen University, Xiamen, Fujian 361005, China
    Cancer Cell 17:560-73. 2010
    ..Here, we report that Sulindac, an NSAID, induces apoptosis by binding to retinoid X receptor-alpha (RXRalpha)...
  2. pmc Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial
    Frank L Meyskens
    Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, California, USA
    Cancer Prev Res (Phila) 1:32-8. 2008
    ..gt; or =3 mm) adenomas were randomly assigned to receive oral difluoromethylornithine (DFMO) 500 mg and sulindac 150 mg once daily or matched placebos for 36 months, stratified by use of low-dose aspirin (81 mg) at baseline ..
  3. ncbi The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15
    Jong Sik Kim
    Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, NIH, MD E4 09, P O Box 12233, 111 TW Alexander Drive, Research Triangle Park, NC 27709, USA
    Mol Cancer Ther 4:487-93. 2005
    ..b>Sulindac sulfide was the most significant NSAID activated gene 1 (NAG-1) inducer and its expression was inversely ..
  4. pmc Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds
    Liqun Huang
    Department of Medicine, Division of Cancer Prevention, Stony Brook University, Stony Brook, New York 11794, USA
    Cancer Res 71:7617-27. 2011
    ..In vivo investigations confirmed the antitumor activity of phospho-aspirin (PA) and phospho-sulindac (PS) in inhibiting tumor growth in established human xenograft models, in which cell proliferation was suppressed ..
  5. pmc The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats
    L Huang
    Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, NY, USA
    Br J Pharmacol 162:1521-33. 2011
    ..We evaluated the anti-inflammatory efficacy and safety of three novel modified NSAIDs, phospho-aspirin, phospho-ibuprofen and phospho-sulindac.
  6. pmc Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice
    Gerardo G MacKenzie
    Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA
    Cancer Prev Res (Phila) 4:1052-60. 2011
    The nonsteroidal anti-inflammatory drug (NSAID) sulindac and the ornithine decarboxylase (ODC) antagonist difluoromethylornithine (DFMO), individually and together, are effective inhibitors of colon carcinogenesis...
  7. pmc Intervening in β-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis
    Ulrike Stein
    Experimental and Clinical Research Center, Charite University Medicine, at the Max Delbrück Center for Molecular Medicine, Berlin, Germany
    Neoplasia 13:131-44. 2011
    ..Here we probe the hypothesis that the nonsteroidal anti-inflammatory drug sulindac sulfide can inhibit colon cancer metastasis by intervening in β-catenin signaling and thereby interdicting ..
  8. pmc Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits
    H M Verheul
    Department of Surgery, Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Br J Cancer 79:114-8. 1999
    ..We found that sulindac was one of the most potent antiangiogenic NSAIDs, inhibiting bFGF-induced neovascularization by 50% and VEGF-..
  9. pmc Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect
    Liqun Huang
    Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA
    Carcinogenesis 31:1982-90. 2010
    Non-steroidal anti-inflammatory drugs such as sulindac are promising chemoprevention agents against colon cancer, but their weak potency and side effects limit their use for both chemoprevention and chemotherapy...
  10. pmc Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice
    Gerardo G MacKenzie
    Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, New York 11794 8173, USA
    Gastroenterology 139:1320-32. 2010
    ..However, chronic administration of NSAIDs is associated with significant side effects, mainly of the gastrointestinal tract. Given these limitations, we synthesized phospho-sulindac (P-S; OXT-328), a novel sulindac derivative.
  11. ncbi Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells
    Pamela L Rice
    Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Mol Cancer Ther 2:885-92. 2003
    ..Substantial clinical, epidemiological, and animal evidence indicate that sulindac and other non-steroidal anti-inflammatory drugs (NSAIDs) prevent the development of CRC...
  12. ncbi Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer
    Naveen Babbar
    Arizona Cancer Center, and Biochemistry, Molecular and Cellular Biology Graduate Program, The University of Arizona, Tucson, 85724, USA
    J Biol Chem 278:47762-75. 2003
    b>Sulindac, a non-steroidal anti-inflammatory prodrug, is metabolized into pharmacologically active sulfide and sulfone derivatives...
  13. ncbi Cyclooxygenase-2 inhibitors in tumorigenesis (Part II)
    M M Taketo
    Laboratory of Biomedical Genetics, Graduate School of Pharmaceutical Sciences, University of Tokyo, Bunkyo, Japan
    J Natl Cancer Inst 90:1609-20. 1998
    ..This Part II (of a two-part review) focuses on the growing clinical and experimental evidence that NSAIDS and COX-2 inhibitors can influence the risk of colon (and possibly of other) cancers...
  14. pmc Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity
    Chi C Wong
    Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, New York 11794 8173, USA
    J Pharmacol Exp Ther 340:422-32. 2012
    ..Kinetic analysis revealed that CES1 is more active in the hydrolysis of phospho-sulindac, phospho-ibuprofen, phospho-naproxen, phospho-indomethacin, and phospho-tyrosol-indomethacin that possessed a ..
  15. pmc Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase
    Dhananjay P Kunte
    Feinberg School of Medicine at Northwestern University, Department of Internal Medicine, Evanston Northwestern Healthcare, 2650 Ridge Avenue, Suite G208, Evanston, IL 60201, USA
    Mol Cancer Ther 7:1797-806. 2008
    ..In the azoxymethane-treated rat model of experimental colon carcinogenesis, sulindac treatment markedly induced Csk with a corresponding increase in inhibitory phosphorylation of Src (Tyr(527))...
  16. ncbi Inhibitory effects of 5-fluorouracil and oxaliplatin on human colorectal cancer cell survival are synergistically enhanced by sulindac sulfide
    Sylwia Flis
    National Medicine Institute, Department of Pharmacology, Warsaw, Poland
    Anticancer Res 29:435-41. 2009
    ..aim of this study was to compare growth inhibitory effects of cytostatics (5-fluorouracil, 5-FU; oxaliplatin) and COX inhibitor sulindac sulfide (an active metabolite of sulindac), given alone or in combination, on several CRC cell lines.
  17. doi A sulindac analogue is effective against malignant pleural effusion in mice
    Charalampos Moschos
    Applied Biomedical Research and Training Center Marianthi Simou and George P Livanos Laboratory, Athens, Greece
    Lung Cancer 73:171-5. 2011
    To examine whether a sulindac derivative (C-18) with previously reported anti-angiogenic properties limits malignant pleural effusion (MPE) formation in mice.
  18. pmc The cyclooxygenase inhibitor sulindac sulfide inhibits EP4 expression and suppresses the growth of glioblastoma cells
    Atsushi Kambe
    Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC 27709, USA
    Cancer Prev Res (Phila) 2:1088-99. 2009
    EP4 expression in human glioblastoma cells correlates with growth on soft agar. The cyclooxygenase inhibitor sulindac sulfide first altered specificity protein-1 (Sp-1) and early growth response gene-1 expression, then increased the ..
  19. pmc JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo
    Zibo Song
    Department of Oncology, Albert Einstein Cancer Center, Bronx, NY 10467, USA
    Eur J Pharmacol 560:95-100. 2007
    Our previous studies demonstrated that sulindac, a non-steroidal anti-inflammatory drug, suppressed intestinal tumor formation in mouse, which is linked to the induction of wild-type p53-activated fragment 1 (p21WAF1, or p21)...
  20. ncbi Nonsteroidal anti-inflammatory drugs and oxidative stress in cancer cells
    M Adachi
    First Department of Internal Medicine, Graduate School of Medicine, Sapporo Medical University, Sapporo, Japan
    Histol Histopathol 22:437-42. 2007
    ..In addition, the classical NSAIDs sulindac and aspirin are promising chemopreventive agents against colon cancer...
  21. ncbi The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis
    N N Mahmoud
    The New York Hospital Cornell University Medical Center, NY 10021, USA
    Carcinogenesis 19:87-91. 1998
    b>Sulindac, a non-steroidal anti-inflammatory drug (NSAID), is effective in treating intestinal adenomas in humans with Familial Adenomatous Polyposis (FAP) and in preventing intestinal tumors in the C57Bl/6J-Min+ (Min) mouse, an animal ..
  22. doi Loss of GDF-15 abolishes sulindac chemoprevention in the ApcMin/+ mouse model of intestinal cancer
    Teresa A Zimmers
    Division of Surgical Oncology, DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
    J Cancer Res Clin Oncol 136:571-6. 2010
    ..We sought to determine the effect of loss of Gdf15 on animal tumor models of hereditary colon cancer and in the NSAID-mediated prevention of heritable colorectal cancer...
  23. ncbi A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer
    R O'CONNOR
    The National Institute for Cellular Biotechnology, Dublin City University, Dublin, 9, Ireland
    Cancer Chemother Pharmacol 59:79-87. 2007
    ..b>Sulindac has been shown to be a competitive substrate for the clinically important resistance protein, multi-drug ..
  24. doi Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer
    Michele T Yip-Schneider
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Pancreas 42:160-7. 2013
    ..dimethylaminoparthenolide (DMAPT), a bioavailable nuclear factor-κB inhibitor, and the cyclooxygenase inhibitors sulindac and celecoxib have potential chemotherapeutic efficacy...
  25. ncbi Sulindac sulfide and caffeic acid phenethyl ester suppress the motility of lung adenocarcinoma cells promoted by transforming growth factor-beta through Akt inhibition
    Yasushi Shigeoka
    Division of Medical Oncology and Molecular Respirology, Faculty of Medicine, Tottori University, 86 Nishimachi, 683 8503 Yonago, Japan
    J Cancer Res Clin Oncol 130:146-52. 2004
    ..Potential chemopreventive agents of cancer-sulindac sulfide, caffeic acid phenethyl ester (CAPE), curcumin, and (+)-catechin-have been reported to interfere with ..
  26. pmc Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients
    Jason A Zell
    Chao Family Comprehensive Cancer Center, Department of Epidemiology, University of California Irvine, 224 Irvine Hall, Irvine, CA 92697, USA
    J Natl Cancer Inst 102:1513-6. 2010
    ..We investigated the effects of ODC1 after treatment with difluoromethylornithine (eflornithine)/sulindac or placebo...
  27. doi A combination of sulindac and arsenic trioxide synergistically induces apoptosis in human lung cancer H1299 cells via c-Jun NH2-terminal kinase-dependent Bcl-xL phosphorylation
    Hyeon Ok Jin
    Laboratory of Radiation Resistance Control, Korea Institute of Radiological and Medical Sciences, Nowon Gu, Seoul, Republic of Korea
    Lung Cancer 61:317-27. 2008
    In the present study, we show that a combination of sulindac and arsenic trioxide (ATO) induces more extensive apoptosis than either drug alone in H1299 human non-small cell lung carcinoma (NSCLC) cells...
  28. ncbi Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells
    Theresia Karl
    Deutsches Krebsforschungszentrum, Forschungsschwerpunkt Angewandte Tumorvirologie, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
    Cancer Lett 245:103-11. 2007
    b>Sulindac, a nonsteroidal anti-inflammatory drug (NSAID), induces growth arrest in HeLa cells and causes strong inhibition of the G1 to S transition of the cell cycle in a concentration-dependent manner...
  29. doi Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps
    Tetsuji Takayama
    Department of Gastroenterology and Oncology, Institutes of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan
    Clin Cancer Res 17:3803-11. 2011
    ..preliminary trial suggesting that aberrant crypt foci (ACF) could be eradicated by short-term administration of sulindac, in the present study, we explored the feasibility of using ACF as surrogate markers for chemoprevention of ..
  30. pmc Sulindac inhibits tumor cell invasion by suppressing NF-κB-mediated transcription of microRNAs
    X Li
    Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA
    Oncogene 31:4979-86. 2012
    ..Here, we show that the NSAID, sulindac sulfide (SS) can potently inhibit the invasion of human MDA-MB-231 breast and HCT116 colon tumor cells in vitro ..
  31. ncbi Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity
    Takae Minami
    First Department of Internal Medicine, Graduate School of Medicine, Sapporo Medical University, Sapporo, Japan
    Clin Cancer Res 11:5248-56. 2005
    The nonsteroidal antiinflammatory drug sulindac is a promising chemopreventive agent against colon cancer...
  32. pmc Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma
    Patricia A Thompson
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724 5024, USA
    Gastroenterology 139:797-805, 805.e1. 2010
    ..We studied effects of the combination of difluoromethylornithine (DFMO) and sulindac on biomarkers and investigated factors that modify their efficacy.
  33. ncbi Sulindac improves memory and increases NMDA receptor subunits in aged Fischer 344 rats
    Michael H Mesches
    Department of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Denver, CO 80262, USA
    Neurobiol Aging 25:315-24. 2004
    ..b>Sulindac, an NSAID that is a nonselective cyclooxygenase (COX) inhibitor was chronically administered to aged Fischer 344 ..
  34. ncbi Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo
    Michele T Yip-Schneider
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Mol Cancer Ther 6:1736-44. 2007
    ..with NF-kappaB inhibition, enhanced the growth suppression of pancreatic cancer cells by the COX inhibitor sulindac in vitro...
  35. ncbi Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study
    Marcia Cruz-Correa
    Department of Medicine, Division of Gastroenterology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Gastroenterology 122:641-5. 2002
    ..b>Sulindac, a nonsteroidal anti-inflammatory drug, causes regression of colorectal adenomas in the retained rectal segment ..
  36. pmc Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas
    Jason A Zell
    Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA
    Cancer Prev Res (Phila) 2:209-12. 2009
    ..of baseline CV risk on adverse CV events in a phase III trial of difluoromethylornithine (DFMO) plus the NSAID sulindac versus placebo in preventing colorectal adenomas. Trial data were analyzed to determine baseline CV risk...
  37. pmc Sulindac suppresses beta-catenin expression in human cancer cells
    Anjia Han
    Department of Pathology, University of Illinois at Chicago, Chicago, IL 60612, USA
    Eur J Pharmacol 583:26-31. 2008
    b>Sulindac has been reported to be effective in suppressing tumor growth through the induction of p21WAF1/cip1 in human, animal models of colon cancer and colon cancer cells...
  38. ncbi Synergistic effects of (-)-epigallocatechin gallate with sulindac against colon carcinogenesis of rats treated with azoxymethane
    Tomokazu Ohishi
    School of Food and Nutritional Sciences, University of Shizuoka, 52 1 Yada, Shizuoka 422 8526, Japan
    Cancer Lett 177:49-56. 2002
    ..b>Sulindac is also well known as a cancer-preventive agent against colon cancer, but its usage is restricted because of its ..
  39. doi Sulindac reverses aberrant expression and localization of beta-catenin in papillary thyroid cancer cells with the BRAFV600E mutation
    Nancy L Cho
    Department of Surgery, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Thyroid 20:615-22. 2010
    ..In this study, we tested the hypothesis that the nonsteroidal antiinflammatory drug sulindac would reverse aberrant beta-catenin activity in thyroid cancer cells.
  40. doi Sulindac induces apoptotic cell death in susceptible human breast cancer cells through, at least in part, inhibition of IKKbeta
    A Mi Seo
    Research Center for Women s Diseases, Division of Biological Sciences, Sookmyung Women s University, Seoul 140 742, Korea
    Apoptosis 14:913-22. 2009
    b>Sulindac is a non-steroidal anti-inflammatory agent with anti-tumor activities that include the induction of apoptosis in various cancer cells and the inhibition malignant transformation...
  41. pmc Sulindac treatment alters collagen and matrilysin expression in adenomas of ApcMin/+ mice
    Hector Guillen-Ahlers
    W M Keck Center for Transgene Research, University of Notre Dame, Notre Dame, IN 46556, USA
    Carcinogenesis 29:1421-7. 2008
    ..In this study, Apc(Min/+) mice, a genetic model of human familial adenomatous polyposis, were treated with sulindac, and these mice demonstrated tumor reduction of >80%, consistent with previous reports...
  42. pmc Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer
    Ka Wing Cheng
    Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, NY, USA
    Int J Oncol 41:1199-203. 2012
    Phospho-sulindac (P-S, OXT-328), a novel sulindac derivative, has shown superior anticancer efficacy and safety compared to sulindac...
  43. ncbi Topical sulindac combined with hydrogen peroxide in the treatment of actinic keratoses
    Lionel Resnick
    Center for Molecular Biology and Biotechnology, Florida Atlantic University, Boca Raton, FL 33431, USA
    J Drugs Dermatol 8:29-32. 2009
    ..b>Sulindac is a Food and Drug Administration (FDA)-approved nonsteroidal anti-inflammatory drug (NSAID) that has been shown ..
  44. ncbi Growth inhibition and apoptosis induction of Sulindac on Human gastric cancer cells
    Y L Wu
    Department of Gastroenterology, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, China
    World J Gastroenterol 7:796-800. 2001
    To evaluate the effects of sulindac in inducing growth inhibition and apoptosis of human gastric cancer cells in comparison with human hepatocellular carcinoma (HCC) cells.
  45. pmc Molecular alterations associated with sulindac-resistant colon tumors in ApcMin/+ mice
    Emily J Greenspan
    Center for Molecular Medicine, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 3101, USA
    Cancer Prev Res (Phila) 3:1187-97. 2010
    Although nonsteroidal anti-inflammatory drugs (NSAID), including sulindac, have been used extensively as chemopreventive agents for colorectal cancer, results are not consistent...
  46. doi A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104
    Ramaswamy Govindan
    Washington University School of Medicine and Alvin J Siteman Cancer Center, St Louis, MO 63110, USA
    J Thorac Oncol 4:220-6. 2009
    ..To assess the efficacy and toxicity of carboplatin, etoposide, and exisulind as initial therapy for extensive stage small cell lung cancer...
  47. pmc Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention
    Paul J Limburg
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    Cancer Prev Res (Phila) 4:259-69. 2011
    b>Sulindac, atorvastatin, or prebiotic dietary fiber may reduce colorectal cancer (CRC) risk. However, clinical trial data are currently limited...
  48. ncbi Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells
    M C Jiang
    Institute of Zoology, Academia Sinica, Taipei, 115, Taiwan
    Biochem Biophys Res Commun 282:671-7. 2001
    ..Aspirin is a cyclooxygenase (COX) inhibitor. Treatment of cells with another COX inhibitor, sulindac, also inhibited MMP-2 activity and increased E-cadherin production of cells...
  49. pmc p27kip1 in intestinal tumorigenesis and chemoprevention in the mouse
    Wancai Yang
    Department of Oncology, Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, NY, USA
    Cancer Res 65:9363-8. 2005
    ..of another cyclin-dependent kinase inhibitor, p21(WAF1/cip1), the nonsteroidal anti-inflammatory drug sulindac was still effective in inhibiting intestinal tumor formation in Apc(+/-),p27(+/-) or Apc(+/-),p27(-/-) mice, ..
  50. ncbi PPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells
    Nikolaos G Nikitakis
    Department of Diagnostic Sciences and Pathology, University of Maryland, Baltimore, MD 21201 1586, USA
    Int J Cancer 98:817-23. 2002
    There is strong evidence that nonsteroidal antiinflammatory drug (NSAID) sulindac may exert a significant antineoplastic effect...
  51. pmc Sulindac sulfide reverses aberrant self-renewal of progenitor cells induced by the AML-associated fusion proteins PML/RARα and PLZF/RARα
    Gunnar Steinert
    Department of Hematology, Goethe University, Frankfurt, Germany
    PLoS ONE 6:e22540. 2011
    ..To better investigate whether NSAID treatment is effective, we used Sulindac Sulfide in X-RARα-positive progenitor cell models...
  52. doi Synthesis, pharmacological evaluation and docking studies of new sulindac analogues
    Nelilma C Romeiro
    Laboratório de Avaliação e Síntese de Substâncias Bioativas LASSBio, Faculdade de Farmacia, Universidade Federal do Rio de Janeiro UFRJ, Rio de Janeiro, PO Box 68023, RJ 21944 970, Brazil
    Eur J Med Chem 44:1959-71. 2009
    This paper describes the synthesis, pharmacological evaluation and docking studies of a series of new sulindac analogues...
  53. ncbi Methylation in the p21WAF1/cip1 promoter of Apc+/-, p21+/- mice and lack of response to sulindac
    Wancai Yang
    Department of Oncology, Montefiore Medical Center, Albert Einstein Cancer Center, 111 East 210th Street, Bronx, NY 10467, USA
    Oncogene 24:2104-9. 2005
    ..and that inactivation of only one p21 allele was also sufficient to abrogate duodenal tumor inhibition by sulindac, a nonsteroidal anti-inflammatory drug...
  54. ncbi [Antitumor effects of sulindac in ovarian cell cultures]
    Anna Jakubowska-Mućka
    Zakład Immunologii, Centrum Onkologii Instytut im Marii Sklodowskiej Curie, Warszawa, Polska
    Ginekol Pol 82:195-9. 2011
    ..The purpose of our study was to assess susceptibility of cells of various ovarian cell lines on different nonsteroidal anti-inflammatory drugs (NSAIDs)...
  55. ncbi Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor
    G Lal
    Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Department of Surgery, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, M5G 1X5 Canada
    Cancer Res 61:6131-6. 2001
    ..to inhibit intestinal polyps in Apc(Delta716) mice more effectively than dual COX-1/COX-2 inhibitors such as sulindac. Various Apc knockout mice, including the multiple intestinal neoplasia (Min) mouse and the Apc(Delta716) mouse, ..
  56. ncbi A case of Cronkhite-Canada syndrome with colorectal adenomas: effect of the nonsteroidal anti-inflammatory drug sulindac
    Kazuoki Hizawa
    Am J Gastroenterol 102:1831-2. 2007
  57. ncbi Sulindac and its metabolites inhibit invasion of glioblastoma cells via down-regulation of Akt/PKB and MMP-2
    Hyung Chahn Lee
    Laboratory of Cell Biology, Department of Laboratory Medicine and Clinical Pathology, Korea Cancer Center Hospital, Seoul 139 240, Korea
    J Cell Biochem 94:597-610. 2005
    Non-steroidal anti-inflammatory drug (NSAID), sulindac has chemopreventive and anti-tumorigenic properties, however, the molecular mechanism of this inhibitory action has not been clearly defined...
  58. pmc Combination of sulindac and dichloroacetate kills cancer cells via oxidative damage
    Kasirajan Ayyanathan
    Center for Molecular Biology and Biotechnology, Charles E Schmidt College of Science, Florida Atlantic University, Jupiter, Florida, United States of America
    PLoS ONE 7:e39949. 2012
    b>Sulindac is an FDA-approved non-steroidal anti-inflammatory drug with documented anticancer activities...
  59. ncbi New TNF-alpha releasing inhibitors as cancer preventive agents from traditional herbal medicine and combination cancer prevention study with EGCG and sulindac or tamoxifen
    Hirota Fujiki
    Department of Biochemistry, Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Yamashiro cho, Tokushima 770 8514, Japan
    Mutat Res 523:119-25. 2003
    ..green tea as a cancer preventive, we review two important results with EGCG: the synergistic effects of EGCG with sulindac or tamoxifen on cancer preventive activity in PC-9 cells, and cancer prevention of intestinal tumor development ..
  60. ncbi Differential activity of sulindac metabolites against squamous cell carcinoma of the head and neck is mediated by p21waf1/cip1 induction and cell cycle inhibition
    Jonathan M Bock
    Department of Otoloryngology, Head and Neck Surgery, University of Iowa Health Care, Iowa City, Iowa 52242, USA
    Cancer Biol Ther 6:30-9. 2007
    b>Sulindac sulfide and sulindac sulfone have demonstrated anti-neoplastic and chemo-preventive activity against various human tumors, but few studies have examined the relative effectiveness of these drugs against squamous cell carcinoma of ..
  61. ncbi Synergistic action of doxorubicin and sulindac in human cervix carcinoma cells - studies on possible mechanisms
    Beata Maria Gruber
    Department of Biochemistry and Biopharmaceuticals, National Medicines Institute, Warsaw, Poland
    Med Sci Monit 16:BR45-51. 2010
    ..The aim of the current work was to study the mechanisms of synergistic action noted in HeLa cervical carcinoma cells under doxorubicin (DOX) and sulindac (SUL) co-treatment.
  62. ncbi The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells
    Tao Zhang
    Division of Genetic and Preventive Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
    J Pharmacol Exp Ther 308:434-7. 2004
    Nonsteroidal anti-inflammatory drugs (NSAIDs) such as sulindac have chemopreventive activity against colorectal tumors...
  63. ncbi Non-steroidal anti-inflammatory agents, tolmetin and sulindac, attenuate oxidative stress in rat brain homogenate and reduce quinolinic acid-induced neurodegeneration in rat hippocampal neurons
    Amichand Dairam
    Faculty of Pharmacy, Rhodes University, P O Box 94, Grahamstown 6140, South Africa
    Metab Brain Dis 21:221-33. 2006
    ..antioxidant and neuroprotective properties of two non-steroidal anti-inflammatory drugs (NSAIDS), tolmetin and sulindac, using quinolinic acid (QA)-induced neurotoxicity as a model...
  64. ncbi Effect of the non-steroidal anti-inflammatory drug sulindac on colorectal adenomas of uncolectomized familial adenomatous polyposis
    Takayuki Matsumoto
    Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    J Gastroenterol Hepatol 21:251-7. 2006
    The aim of the present study was to elucidate the effect of sulindac on uncolectomized familial adenomatous polyposis (FAP).
  65. doi The non-steroidal anti-inflammatory drugs Sulindac sulfide and Diclofenac induce apoptosis and differentiation in human acute myeloid leukemia cells through an AP-1 dependent pathway
    Raminder Singh
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Apoptosis 16:889-901. 2011
    ..CD34(+) selected de novo AML patient samples and the AML cell lines THP-1 and HL-60 were treated with the NSAIDs Sulindac sulfide and Diclofenac...
  66. pmc Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity
    Clara Curiel-Lewandrowski
    College of Medicine, Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724 5024, USA
    Cancer 118:5848-56. 2012
    ..However, the ability of NSAIDs to reach melanocytes in vivo and modulate key biomarkers in preneoplastic lesions such as atypical nevi has not been evaluated...
  67. ncbi Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac
    Li Ma
    Department of Gastroenterology, Second Affiliated Hospital, Lanzhou Medical University, Lanzhou 730000, Gansu Province, China
    World J Gastroenterol 11:1829-32. 2005
    To investigate the effects of mitomycin (MMC) combined with sulindac on cell viability, apoptotic induction and expression of apoptosis-related gene Bcl-2 and cyclooxygenase-2 (COX-2) in gastric cancer SGC-7901 cells.
  68. ncbi Antiproliferative effects of S-allylmercaptocysteine on colon cancer cells when tested alone or in combination with sulindac sulfide
    H Shirin
    Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Cancer Res 61:725-31. 2001
    ..For comparison, we included the compound sulindac sulfide (SS), because sulindac compounds are well-established colon cancer chemopreventive agents...
  69. ncbi Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer?
    F Tonelli
    Department of Clinical Physiopathology, Surgical Unit, University of Florence, Italy
    J Surg Oncol 74:15-20. 2000
    Ileorectal anastomosis (IRA) is still used in the treatment of familial adenomatous polyposis (FAP). Sulindac appears to induce regression of colorectal adenomas; however, its effects in long-term therapy and in preventing carcinoma ..
  70. ncbi The influence of sulindac on experimental streptozotocin-induced diabetic neuropathy
    D W Zochodne
    Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
    Can J Neurol Sci 21:194-202. 1994
    We studied the influence of sulindac, a nonsteroidal anti-inflammatory agent on experimental streptozotocin-induced diabetic neuropathy...
  71. ncbi A phase II trial of carboplatin and gemcitabine with exisulind (IND #65,056) in patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (E1501)
    Gregory A Masters
    Christiana Care CCOP, Newark, Delaware, USA
    J Thorac Oncol 1:673-8. 2006
    ..The oral proapoptotic agent exisulind is a cyclic guanosine monophosphate phosphodiesterase that increases apoptosis in vitro. We performed a phase II trial of carboplatin and gemcitabine with exisulind in patients with advanced NSCLC...
  72. doi Sulindac sulfide induces autophagic death in gastric epithelial cells via survivin down-regulation: a mechanism of NSAIDs-induced gastric injury
    Shiun Kwei Chiou
    Department of Veterans Affairs Medical Center, Long Beach, CA 90822 5201, USA
    Biochem Pharmacol 81:1317-23. 2011
    b>Sulindac sulfide, a nonsteroidal anti-inflammatory drug (NSAID), has anti-tumorigenic and anti-inflammatory activities, but causes gastric mucosal damage...
  73. ncbi Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer
    Tien Hoang
    Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio, USA
    J Thorac Oncol 1:218-25. 2006
    ..The study was designed to evaluate the safety and efficacy of exisulind, a selective apoptotic antineoplastic drug, in combination with gemcitabine as second-line therapy in patients with progressing advanced non-small cell lung cancer...
  74. pmc Growth compensatory role of sulindac sulfide-induced thrombospondin-1 linked with ERK1/2 and RhoA GTPase signaling pathways
    Yuseok Moon
    Department of Microbiology and Immunology and Medical Research Institute, Pusan National University School of Medicine, Busan, 602 739, Republic of Korea
    Life Sci 82:591-9. 2008
    ..Among diverse NSAIDs, sulindac sulfide was most potent of inducing the human TSP-1 protein expression...
  75. ncbi Sulindac suppresses tumorigenesis in the Min mouse
    Y Beazer-Barclay
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Carcinogenesis 17:1757-60. 1996
    ..of this model for the evaluation and optimization of chemopreventive agents, we examined the effects of sulindac on tumorigenesis in Min mice as this compound can inhibit colorectal tumorigenesis in human familial adenomatous ..
  76. ncbi Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis
    Natalia A Ignatenko
    Department of Cell Biology and Anatomy, Arizona Cancer Center, The University of Arizona, Tucson, USA
    Nutr Cancer 56:172-81. 2006
    The nonsteroidal antiinflammatory drug sulindac displays chemopreventive activity in patients with familial adenomatous polyposis (FAP)...
  77. ncbi Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma
    Victoria J Sinibaldi
    Prostate Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Am J Clin Oncol 29:395-8. 2006
    ....
  78. ncbi Effects of long-term administration of sulindac on APC mRNA and apoptosis in colons of rats treated with azoxymethane
    Y Kishimoto
    Division of Pharmacotherapeutics, Department of Pathophysiological and Therapeutic Science, Faculty of Medicine, Tottori University, 86 Nishicho, Yonago 683 8503, Japan
    J Cancer Res Clin Oncol 128:589-95. 2002
    Non-steroidal anti-inflammatory drugs, including sulindac, have been shown to exhibit anti-colon cancer activity; however, the detailed mechanisms concerning continuous long-term administration are still unclear...
  79. ncbi Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases
    Jung Hyun Park
    Department of Internal Medicine, Institute of Wonkwang Medical Science, Wonkwang University, School of Medicine, Jeonbuk 570 749, South Korea
    Oncol Rep 20:379-84. 2008
    ..b>Sulindac is known to enhance the cellular responsiveness of tumors toward chemotherapeutic drugs...
  80. ncbi Mechanisms of sulindac-induced apoptosis and cell cycle arrest
    Barbara Jung
    Department of Molecular Biology, Sidney Kimmel Cancer Center, 10835 Altman Row, San Diego, CA 92121, USA
    Cancer Lett 219:15-25. 2005
    The mechanism underlying the chemopreventive effects of the non-steroidal anti-inflammatory drug sulindac remains unclear. Its active metabolite, sulindac sulfide, induces cell cycle arrest as well as apoptosis in mammalian cell lines...
  81. ncbi A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer
    Christopher W Ryan
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239 3098, USA
    BJU Int 95:963-8. 2005
    To determine the safety and efficacy, in a dose-escalation study, of exisulind (an oral sulphone metabolite of sulindac thought to induce apoptosis in malignant cells by inhibiting cGMP-phosphodiesterase) combined with docetaxel in men ..
  82. doi Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations
    Svenja D Steinbrink
    Institute of Pharmaceutical Chemistry ZAFES, Goethe University, Max von Laue Str 9, 60438, Frankfurt Main, Germany
    Cell Mol Life Sci 67:797-806. 2010
    b>Sulindac is a non-selective inhibitor of cyclooxygenases (COX) used to treat inflammation and pain...
  83. ncbi Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis
    J J Keller
    Department of Pathology, Academic Medical Center, 1100 DD Amsterdam, The Netherlands
    Clin Cancer Res 7:4000-7. 2001
    b>Sulindac causes the reduction of adenomas in familial adenomatous polyposis (FAP) patients, but complete regression is unusual, and breakthrough of colorectal carcinoma during sulindac treatment has been described...
  84. ncbi A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer
    Suzanne F Jones
    The Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN 37203, USA
    Clin Lung Cancer 6:361-6. 2005
    Exisulind is a sulfone derivative of sulindac that induces apoptosis and demonstrates synergy with docetaxel in lung cancer models...
  85. ncbi Up-regulation of early growth response gene 1 (EGR-1) via ERK1/2 signals attenuates sulindac sulfide-mediated cytotoxicity in the human intestinal epithelial cells
    Yuseok Moon
    Department of Microbiology and Immunology and Medical Research Institute, Pusan National University School of Medicine, Busan, 602 739, Republic of Korea
    Toxicol Appl Pharmacol 223:155-63. 2007
    ..In the present study, NSAID sulindac sulfide was investigated for the cytotoxic injury in the intestinal epithelial cells in association with an ..
  86. ncbi Autophagy delays sulindac sulfide-induced apoptosis in the human intestinal colon cancer cell line HT-29
    C Bauvy
    INSERM U504 Glycobiologie et Signalisation Cellulaire, 16, avenue Paul-Vaillant Couturier, 94807 Villejuif Cedex, France
    Exp Cell Res 268:139-49. 2001
    ..that 3-methyladenine, an inhibitor of autophagy, increases the sensitivity of HT-29 cells to apoptosis induced by sulindac sulfide, a nonsteroidal anti-inflammatory drug which inhibits the cyclooxygenases...
  87. ncbi Non-steroidal anti-inflammatory agents, tolmetin and sulindac, inhibit liver tryptophan 2,3-dioxygenase activity and alter brain neurotransmitter levels
    A Dairam
    Faculty of Pharmacy, Rhodes University, Grahamstown, South Africa
    Life Sci 79:2269-74. 2006
    ..In this study, we determined the effect of the non-steroidal anti-inflammatory agents, tolmetin and sulindac, on rat liver TDO activity and the subsequent changes in the hippocampal and striatal neurotransmitter levels...
  88. ncbi Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta)
    Dae J Kim
    Department of Veterinary and Biomedical Sciences and The Center for Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA, 16802, USA
    Carcinogenesis 27:1105-12. 2006
    ..32 g sulindac/kg diet...
  89. ncbi Combined effect of arsenic trioxide and sulindac sulfide in A549 human lung cancer cells in vitro
    T T Jiang
    Dept of Radiation Oncology, Henry Ford Health Sciences Center, Detroit, Michigan 48098, USA
    J Exp Clin Cancer Res 23:259-62. 2004
    ..In this study we tested sulindac sulfide, a nonsteroidal anti-inflammatory drug (NSAID) to test its effects with arsenic...
  90. ncbi Both PPARgamma and PPARdelta influence sulindac sulfide-mediated p21WAF1/CIP1 upregulation in a human prostate epithelial cell line
    Morag C Jarvis
    Biomedical Research Centre, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK
    Oncogene 24:8211-5. 2005
    Nonsteroidal anti-inflammatory drugs (NSAIDs) including sulindac sulfide are known to exert cancer chemopreventative activity in a range of cell lines...
  91. ncbi Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis
    Russell F Jacoby
    University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, USA
    Gastroenterology 127:838-44. 2004
    ..epidemiological data, and clinical trials in patients with adenomatous polyposis have consistently indicated that sulindac and other nonsteroidal antiinflammatory drugs or cyclooxygenase inhibitors have the greatest potential efficacy ..
  92. ncbi Defective acute apoptotic response to genotoxic carcinogen in small intestine of APC(Min/+) mice is restored by sulindac
    Ying Hu
    Department of Medicine, Flinders University of South Australia, Adelaide, Australia
    Cancer Lett 248:234-44. 2007
    ..effect of APC loss on azoxymethane (AOM)-induced apoptosis and cell proliferation, as well as their regulation by sulindac was examined in colon and small intestine in APC(Min/+) mice...
  93. ncbi Selective inhibitors of MEK1/ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells
    Yunjie Sun
    Division of Gastroenterology Hepatology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Mol Cancer Ther 4:51-9. 2005
    The nonsteroidal anti-inflammatory drug (NSAID) sulindac prevents experimental colon cancer and can regress precancerous polyps in humans...
  94. ncbi Combination of tumor necrosis factor-alpha with sulindac in human carcinoma cells in vivo
    Hiroshi Yasui
    First Department of Internal Medicine, Sapporo Medical University School of Medicine, S 1, W 16, Chuo Ku, Sapporo, 060 8543, Japan
    Ann N Y Acad Sci 1010:273-7. 2003
    ..Recently, the nonsteroidal anti-inflammatory drug (NSAID) sulindac and its metabolites have been shown to inhibit the NF-kappaB-mediated survival signals through inhibition of IKK-..
  95. ncbi Sulindac corrects defective apoptosis and suppresses azoxymethane-induced colonic oncogenesis in p53 knockout mice
    Ying Hu
    Department of Medicine Flinders University of South Australia, Adelaide, Australia
    Int J Cancer 116:870-5. 2005
    ..We tested the ability of sulindac to reverse these defects...
  96. ncbi High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors
    N Julian H Sturt
    Cancer 101:652; author reply 653. 2004
  97. ncbi Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction
    Sung Keum Seo
    Laboratory of Functional Genomics, Korea Institute of Radiological and Medical Sciences, 215 4 Gongneung dong, Nowon Ku, Seoul, 139 706, Republic of Korea
    Apoptosis 12:195-209. 2007
    ..The purpose of this study was to elucidate the potential signaling components underlying sulindac-induced apoptosis in human multiple myeloma (MM) cells...
  98. ncbi Response of Apc(min) and A33 (delta N beta-cat) mutant mice to treatment with tea, sulindac, and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)
    Gayle A Orner
    Department of Environmental and Molecular Toxicology, 571 Weniger Hall, Linus Pauling Institute, Oregon State University, Corvallis, OR 97331 6512, USA
    Mutat Res 506:121-7. 2002
    ..Res. 495 (2001) 61]. We compared the inhibitory effects of white and green teas with sulindac, a nonsteroidal anti-inflammatory agent, in two different mouse models of intestinal tumorigenesis...
  99. pmc Primary chemoprevention of familial adenomatous polyposis with sulindac
    Francis M Giardiello
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA
    N Engl J Med 346:1054-9. 2002
    ..Nonsteroidal antiinflammatory drugs can cause regression of adenomas, but whether they can prevent adenomas is unknown...
  100. ncbi Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L)
    Rajani Ravi
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1000, USA
    Cancer Res 62:1583-7. 2002
    ..either a peptide that disrupts the inhibitor of kappaB kinase complex or the nonsteroidal anti-inflammatory drug, sulindac sulfide...
  101. ncbi Sulindac to prevent recurrent preterm labor: a randomized controlled trial
    R G Humphrey
    Department of Obstetrics and Gynecology, Arnold Palmer Hospital for Children and Women, Orlando, Florida, USA
    Obstet Gynecol 98:555-62. 2001
    OBJECTIVE: To assess the efficacy of oral sulindac in low doses for prolonged duration to decrease the risk of recurrent preterm labor and extend gestation...

Research Grants73

  1. Combined Chemoprevention in Beta-Catenin Mutant Mice
    Gayle Orner; Fiscal Year: 2004
    ..A combination of tea plus the NSAID sulindac was recently shown to be highly effective at preventing the formation of tumors in Apc[min] mice...
  2. Using Mouse Endoscopy for Evaluating Colon Cancer
    Daniel Rosenberg; Fiscal Year: 2009
    ..We will use sulindac, currently being tested in an NCI multi-center pilot chemoprevention clinical trial (CPN), as a model ..
  3. Using Mouse Endoscopy for Evaluating Colon Cancer
    DANIEL WILLIAM ROSENBERG; Fiscal Year: 2010
    ..We will use sulindac, currently being tested in an NCI multi-center pilot chemoprevention clinical trial (CPN), as a model ..
  4. Combined effects of tea plus NSAIDS towards colon cancer
    Gayle Orner; Fiscal Year: 2004
    ..Our preliminary data shows that tea or a combination of tea plus the NSAID sulindac is highly effective at preventing the formation of tumors in Apc m/In mice...
  5. Dual Modality System for Imaging Colon Cancer in Mice
    Jennifer Kehlet Barton; Fiscal Year: 2010
    ..progress to adenoma and/or adenocarcinoma? b) Can treatment with 1-difluoromethylornithine (DFMO) and/or sulindac regress adenoma and prevent adenocarcinoma? c) What role does the RAS oncogene play in sulindac prevention of ..
  6. A novel mouse colon cancer model and chemoprevention
    Wei Dai; Fiscal Year: 2007
    ..Moreover, chemopreventive compounds such as sulindac sulfide and S-allylmercaptocysteine are capable of inducing apoptosis in HT-29 and SW-480 colon tumor cells; ..
  7. Novel mouse colon cancer models and chemoprevention
    Wei Dai; Fiscal Year: 2007
    ..Moreover, chemopreventive compounds such as sulindac sulfide and S-allylmercaptocysteine are capable of inducing apoptosis in HT-29 and SW-480 colon tumor cells; ..
  8. A novel mouse colon cancer model and chemoprevention
    Wei Dai; Fiscal Year: 2010
    ..Moreover, chemopreventive compounds such as sulindac sulfide and S-allylmercaptocysteine are capable of inducing apoptosis in HT-29 and SW-480 colon tumor cells;BubRl ..
  9. Novel mouse colon cancer models and chemoprevention
    Wei Dai; Fiscal Year: 2009
    ..Moreover, chemopreventive compounds such as sulindac sulfide and S-allylmercaptocysteine are capable of inducing apoptosis in HT-29 and SW-480 colon tumor cells; ..
  10. CLINICAL PHARMACOLOGY OF NSAIDS IN THE ELDERLY
    D Brater; Fiscal Year: 1992
    ..In the former, we will use balance and clearance techniques to examine the effects of ibuprofen, sulindac and piroxicam on renal function...
  11. Chemoprevention of Tobacco Related Cancer in Animals
    Michael Pereira; Fiscal Year: 2004
    ..budesonide and the farnesyl transferase inhibitor, R115777 in the lung studies and budesonide, ketoprofen and sulindac in the bladder study...
  12. BIOADHESIVE MICROSPHERES FOR COLON CANCER THERAPY
    NEJAT EGILMEZ; Fiscal Year: 2002
    ..Following their loading with either sulindac (a nonsteroidal anti-inflammatory drug with antitumor activity) and/or Interleukin-12 (a potent immunostimulatory ..
  13. Colon Cancer Prevention with Phospho-Sulindac
    Basil Rigas; Fiscal Year: 2009
    A significant development in combination chemoprevention is the use of sulindac plus difluoromethylornithine (DFMO), which was recently demonstrated to reduce the recurrence of all human colon adenomas by 69% and of advanced adenomas by ..
  14. Colon Cancer Prevention with Phospho-Sulindac
    Basil Rigas; Fiscal Year: 2010
    A significant development in combination chemoprevention is the use of sulindac plus difluoromethylornithine (DFMO), which was recently demonstrated to reduce the recurrence of all human colon adenomas by 69% and of advanced adenomas by ..
  15. Characterization of a novel nuclear Rab protein
    Ying Huang; Fiscal Year: 2007
    ..expression is down-regulated by apoptosis inducing agents such as ultraviolet radiation (UV), thapsigargin and sulindac sulfide...
  16. Colonoscopic Analysis of Response of Murine Colon Lesions to Drug Intervention
    MARGIE CLAPPER; Fiscal Year: 2007
    ..the heterogeneous inhibitory response of colon adenomas to the nonsteroidal anti-inflammatory drug (NSAID) sulindac as seen in humans...
  17. Modulation of carcinogen-metabolizing enzyzmes by sulindac
    Henry Ciolino; Fiscal Year: 2007
    ..One promising colon chemopreventive agent is sulindac, a non-steroidal anti-inflammatory drug (NSAID) routinely prescribed to alleviate chronic pain and inflammation...
  18. Characterization of a novel ER membrane protein SPOC
    Ying Huang; Fiscal Year: 2005
    ..Thapsigargin and sulindac sulfide are known to perturb intracellular Ca2+ homeostasis by promoting ER Ca2+ pool depletion...
  19. Altered Arachidonic Acid Balance and Colon Cancer
    Daniel Rosenberg; Fiscal Year: 2007
    ..Aim 3 will test the influence of cPLA2 on chemoprevention by the Cox inhibitor, sulindac. Efficacy will be evaluated in mice with normal or reduced levels of cPLA2...
  20. Altered Arachidonic Acid Balance and Colon Cancer
    DANIEL WILLIAM ROSENBERG; Fiscal Year: 2010
    ..Aim 3 will test the influence of cPLA2 on chemoprevention by the Cox inhibitor, sulindac. Efficacy will be evaluated in mice with normal or reduced levels of cPLA2...
  21. Enhanced Killing of Cancer Cell by Sulindac and Oxidative Stress
    Herbert Weissbach; Fiscal Year: 2007
    b>Sulindac is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenases (COX) 1 and 2. It is a prodrug which in the body is converted to the active COX inhibitor, sulindac sulfide...
  22. Altered Arachidonic Acid Balance and Colon Cancer
    Daniel Rosenberg; Fiscal Year: 2006
    ..Aim 3 will test the influence of cPLA2 on chemoprevention by the Cox inhibitor, sulindac. Efficacy will be evaluated in mice with normal or reduced levels of cPLA2...
  23. Planning a Trial of Sulindac for Oral Leukoplakia
    Jay Boyle; Fiscal Year: 2005
    Funding is requested to plan a multi-center, randomized, double-blind, placebo-controlled chemoprevention trial of sulindac for oral leukoplakia through an international collaboration between Memorial Sloan-Kettering Cancer Center (MSKCC) ..
  24. SMAC in chemoprevention of colon cancer
    Lin Zhang; Fiscal Year: 2010
    ..Furthermore, activation of SMAC and agents that mimic the function of SMAC can enhance the apoptotic response to sulindac, an NSAID commonly used in chemoprevention...
  25. SMAC in chemoprevention of colon cancer
    Lin Zhang; Fiscal Year: 2009
    ..Agents that mimic the function of SMAC can enhance the apoptotic response to sulindac, an NSAID commonly used in chemoprevention...
  26. SMAC in chemoprevention of colon cancer
    Lin Zhang; Fiscal Year: 2007
    ..Furthermore, activation of SMAC and agents that mimic the function of SMAC can enhance the apoptotic response to sulindac, an NSAID commonly used in chemoprevention...
  27. Chemopreventive Effect of NSAIDs Against Prostate Cancer
    Bhagavathi Narayanan; Fiscal Year: 2009
    ..It is not clear however, whether selective COX-2 inhibitors, or exisulind, a metabolic product of sulindac (NSAID), exert their potentially beneficial effects either by blocking COX-2 or by stimulating programmed cell ..
  28. Modulation of Intestinal Tumorigenesis
    Leonard Augenlicht; Fiscal Year: 2002
    ..We will pursue the p21 gene dosage effect on tumor formation and response to sulindac that we reported...
  29. ESOPHAGEAL ADENOCARCINOGENESIS AND ITS PREVENTION
    Chung Yang; Fiscal Year: 2001
    ..3) To investigate the possible inhibition of BE/EAC formation by nonsteroidal anti-inflammatory drugs (NSAIDs). Sulindac, sulindac sulfone, and selective cyclooxygenase 2 (COX-2) inhibitors will be used to examine the roles of ..